Literature DB >> 16052531

Effective inhibition of cell growth and invasion of melanoma by combined suppression of BRAF (V599E) and Skp2 with lentiviral RNAi.

Hidetoshi Sumimoto1, Kenro Hirata, Shizuko Yamagata, Hiroyuki Miyoshi, Makoto Miyagishi, Kazunari Taira, Yutaka Kawakami.   

Abstract

p27Kip1 that regulates the G1/S transition of cell cycle and inhibits Rho A signaling is frequently lost in several cancers leading to the deregulation of cell growth and cell motility. Mitogen-activated protein kinases (MAPK) regulate the export of p27Kip1 from nucleus to cytoplasm, followed by the degradation with proteases. Skp-2, a subunit of an SCF ubiquitin-protein ligase complex responsible for the ubiquitination of p27Kip1, is upregulated frequently in several cancers, leading to the decrease of p27Kip1. We applied human immunodeficiency virus (HIV) lentivirus-mediated RNA interference (RNAi) to melanoma cells with the BRAF mutation (V599E) and overexpressed Skp-2 and found that the simultaneous suppression of these activated oncogenes resulted in the effective inhibition of in vitro cell growth and invasive ability of melanoma cells accompanied by the additional increase of p27Kip1. Our results suggest that gene therapy against melanoma with the enhanced MAPK and ubiquitin-proteasomal pathways could be a specific and effective therapeutic strategy for cancers. Copyright 2005 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16052531     DOI: 10.1002/ijc.21286

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  17 in total

Review 1.  Therapeutic application of RNAi: is mRNA targeting finally ready for prime time?

Authors:  Dirk Grimm; Mark A Kay
Journal:  J Clin Invest       Date:  2007-12       Impact factor: 14.808

Review 2.  Targeting BRAF mutant metastatic colorectal cancer: clinical implications and emerging therapeutic strategies.

Authors:  Jeanne Tie; Jayesh Desai
Journal:  Target Oncol       Date:  2014-08-15       Impact factor: 4.493

3.  BRAF V600E maintains proliferation, transformation, and tumorigenicity of BRAF-mutant papillary thyroid cancer cells.

Authors:  Dingxie Liu; Zhi Liu; Stephen Condouris; Mingzhao Xing
Journal:  J Clin Endocrinol Metab       Date:  2007-03-20       Impact factor: 5.958

Review 4.  Small molecule therapeutics targeting F-box proteins in cancer.

Authors:  Yuan Liu; Rama K Mallampalli
Journal:  Semin Cancer Biol       Date:  2015-09-30       Impact factor: 15.707

Review 5.  RNAi: a potential new class of therapeutic for human genetic disease.

Authors:  Attila A Seyhan
Journal:  Hum Genet       Date:  2011-05-03       Impact factor: 4.132

Review 6.  Role of SKP1-CUL1-F-box-protein (SCF) E3 ubiquitin ligases in skin cancer.

Authors:  Chuan-Ming Xie; Wenyi Wei; Yi Sun
Journal:  J Genet Genomics       Date:  2013-02-10       Impact factor: 4.275

7.  Role of siRNA silencing of MMP-2 gene on invasion and growth of laryngeal squamous cell carcinoma.

Authors:  Yanan Sun; Ming Liu; Baofeng Yang; Baoxin Li; Jianguang Lu
Journal:  Eur Arch Otorhinolaryngol       Date:  2008-04-25       Impact factor: 2.503

8.  Specific small molecule inhibitors of Skp2-mediated p27 degradation.

Authors:  Lily Wu; Arsen V Grigoryan; Yunfeng Li; Bing Hao; Michele Pagano; Timothy J Cardozo
Journal:  Chem Biol       Date:  2012-12-21

9.  Skp2 regulates G2/M progression in a p53-dependent manner.

Authors:  Rong Hu; Andrew E Aplin
Journal:  Mol Biol Cell       Date:  2008-08-20       Impact factor: 4.138

Review 10.  Understanding signaling cascades in melanoma.

Authors:  Pablo Lopez-Bergami; Boris Fitchman; Ze'ev Ronai
Journal:  Photochem Photobiol       Date:  2007-12-15       Impact factor: 3.421

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.